Webinar video | Life Sciences Session #3: ‘Trop is te veel’: what not to do in case of pricing of medicines?
The COVID-19 pandemic challenges companies and firms worldwide, and requires us all to adopt new proactive approaches. While COVID-19 prevents us from being together, our Life Sciences team takes the initiative to give you short, digestible and regular online Life Sciences Sessions.
Are you trying to see the wood for the trees when setting prices and arranging reimbursement for you medicines in Belgium? Is “the sky the limit” for your medicines’ prices? Or are you also wondering what all the fuzz is about the Commission’s decision towards Aspen?
- Kirian Claeyé will guide you through the regulatory maze of pricing and reimbursement of medicines in Belgium.
- Beatrijs Gielen and Nina Methens will clarify the European Courts’ approach towards excessive pricing under competition law, in particular in the pharma sector, and will discuss the long-awaited European Commission settlement decision in the Aspen case.
Recommended articles
Belgian Parliament has adopted urgent 2026 healthcare budget measures: what’s the impact on the pharma industry?
Over the Christmas break, the Belgian Parliament adopted an urgent law with several measures linked to the approved 2026 healthcare budget, with effect from 1 January 2026. The law is intentionally limited to provisions that must enter into force immediately to ensure that the required savings and revenues are available from the start of the […]
Read on
EU Reaches Pharma Package Deal: Key Changes at a Glance
On 11 December 2025, following overnight negotiations, the Council and the European Parliament announced a political agreement on the long-awaited Pharma Package (see here). The reform seeks to update the EU’s pharmaceutical rulebook to facilitate access to safe and affordable treatments and bolster the life sciences sector’s competitiveness. While more detailed information is still trickling […]
Read on
Belgian Constitutional Court strikes down pharma industry ‘unavailability contribution’
The Belgian Constitutional Court (“CC”), on 6 November 2025, annulled some provisions of the Law of 18 May 2024 containing various provisions on health and finance, striking down the pharma industry ‘unavailability contribution’. Background Parts of the above Law sought to protect patients from bearing additional costs when reimbursable medicines become unavailable and must be […]
Read on